Ulcerative colitis-related spondyloarthritis treated with golimumab until 27 weeks of gestation

Although tumor necrosis factor inhibitors are recommended for preventing flare-ups in pregnant women with ulcerative colitis (UC), studies on golimumab use during pregnancy are scant. Herein, we present a 39-year-old woman with UC and spondyloarthritis. The patient preferred treatment with a long dosing interval that minimally affects the working life of the patient. Golimumab, considering its long dosing interval, was prescribed after discussion with the patient, physician and pharmacists. Clinical remission was achieved during pregnancy, and the patient delivered a healthy baby. The vaccines were administered according to the vaccine schedule: during the first year after birth, there were neither infections caused by live vaccines nor diseases that the administered vaccines are meant to prevent. Overall, this case suggests that golimumab treatment during pregnancy may be compatible; however, further evaluations, including drug-level analysis, are needed.